Understanding disease symptoms and impacts and producing qualitatively-derived severity stages for MPS IIIA: a mixed methods approach.
MPS IIIA
Natural history study
Qualitative research
Thematic analysis
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
22 02 2022
22 02 2022
Historique:
received:
13
09
2021
accepted:
06
02
2022
entrez:
23
2
2022
pubmed:
24
2
2022
medline:
14
4
2022
Statut:
epublish
Résumé
MPS IIIA is a rare, degenerative pediatric genetic disease characterized by symptoms impacting cognition, mobility and behavior; the mean age of death is around 15 years of age. Currently, there are no approved therapies for MPS IIIA. A two-year, multi-center, prospective, descriptive cohort study was conducted to document the natural history course of MPS IIIA. In the context of this study, semi-structured interviews were performed with parents of children at study entry and one year later. Interview transcripts were analyzed using thematic analysis methods to identity concepts of interest to children and parents, identify what factors impacted parents' burden the most, and develop qualitatively-derived disease severity stages. Children were sorted into these stages according to the symptoms their parents described at the entry interview. This sorting was compared quantitatively to the sorting of children at baseline according to the child's calendar age and their BSID development quotient (DQ). 22 parents in France, Germany, the Netherlands and the UK were interviewed. Children ranged in age from 28 to 105 months (mean 61.4 months). The conceptual models for children's symptoms and impacts and parents' impacts provided a detailed and comprehensive picture of what it is like for children of various ages and their parents to live with MPS IIIA. Four factors were identified as mediating the burden perceived by parents: state support, family support, time since diagnosis, and parent coping strategy. Four disease stages were developed, accounting for both the presence and the severity of MPS IIIA symptoms. The comparison of children's sorting into these stages with the BSID DQ and the child's calendar age showed strong statistical associations. The findings of this qualitative research embedded in a natural history study add to the current understanding of MPS IIIA as a complex disease that impacts every aspect of the lives of children and their families. This study demonstrates the unique potential of mixed methods research in rare diseases to address some of the current limitations of more traditional quantitative approaches by providing an individualized, detailed understanding of the patient experience.
Sections du résumé
BACKGROUND
MPS IIIA is a rare, degenerative pediatric genetic disease characterized by symptoms impacting cognition, mobility and behavior; the mean age of death is around 15 years of age. Currently, there are no approved therapies for MPS IIIA.
METHODS
A two-year, multi-center, prospective, descriptive cohort study was conducted to document the natural history course of MPS IIIA. In the context of this study, semi-structured interviews were performed with parents of children at study entry and one year later. Interview transcripts were analyzed using thematic analysis methods to identity concepts of interest to children and parents, identify what factors impacted parents' burden the most, and develop qualitatively-derived disease severity stages. Children were sorted into these stages according to the symptoms their parents described at the entry interview. This sorting was compared quantitatively to the sorting of children at baseline according to the child's calendar age and their BSID development quotient (DQ).
RESULTS
22 parents in France, Germany, the Netherlands and the UK were interviewed. Children ranged in age from 28 to 105 months (mean 61.4 months). The conceptual models for children's symptoms and impacts and parents' impacts provided a detailed and comprehensive picture of what it is like for children of various ages and their parents to live with MPS IIIA. Four factors were identified as mediating the burden perceived by parents: state support, family support, time since diagnosis, and parent coping strategy. Four disease stages were developed, accounting for both the presence and the severity of MPS IIIA symptoms. The comparison of children's sorting into these stages with the BSID DQ and the child's calendar age showed strong statistical associations.
CONCLUSIONS
The findings of this qualitative research embedded in a natural history study add to the current understanding of MPS IIIA as a complex disease that impacts every aspect of the lives of children and their families. This study demonstrates the unique potential of mixed methods research in rare diseases to address some of the current limitations of more traditional quantitative approaches by providing an individualized, detailed understanding of the patient experience.
Identifiants
pubmed: 35193633
doi: 10.1186/s13023-022-02208-w
pii: 10.1186/s13023-022-02208-w
pmc: PMC8864874
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
75Informations de copyright
© 2022. The Author(s).
Références
Orphanet J Rare Dis. 2020 Jun 3;15(1):134
pubmed: 32493385
J Inherit Metab Dis. 2014 May;37(3):431-7
pubmed: 24271936
Acta Paediatr. 2013 May;102(5):462-70
pubmed: 23336697
Neurol Ther. 2021 Jun;10(1):197-212
pubmed: 33263924
J Pediatr. 2016 Mar;170:278-87.e1-4
pubmed: 26787381
Orphanet J Rare Dis. 2017 Oct 23;12(1):168
pubmed: 29061114
Mol Genet Metab. 2017 Jul;121(3):227-240
pubmed: 28595941
Am J Med Genet A. 2011 Jan;155A(1):58-68
pubmed: 21204211
Ann Rehabil Med. 2018 Apr;42(2):313-320
pubmed: 29765885
Ann Neurol. 2010 Dec;68(6):876-87
pubmed: 21061399
Int J Mol Sci. 2018 Oct 08;19(10):
pubmed: 30297617
J Inherit Metab Dis. 2015 Mar;38(2):323-31
pubmed: 25048386
Value Health. 2017 Jul - Aug;20(7):838-855
pubmed: 28712612
Metab Brain Dis. 2018 Feb;33(1):1-10
pubmed: 28921412
J Inherit Metab Dis. 2008 Apr;31(2):240-52
pubmed: 18392742
Orphanet J Rare Dis. 2018 Jun 18;13(1):95
pubmed: 29914528
Mol Genet Metab. 2020 Sep - Oct;131(1-2):181-196
pubmed: 32917509
Pediatrics. 2017 Jun;139(6):
pubmed: 28562301